GREGoRi Innovation Projects (U01 Clinical Trial Optional)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Human Genome Research Institute (NHGRI) is launching an initiative to support proof of concept studies aimed at uncovering novel strategies for identifying genes or genetic variants responsible for rare disorders. This initiative seeks to advance beyond traditional DNA sequencing methods by encouraging research that employs emerging molecular technologies such as multi-omics, RNA sequencing, or methylation analysis as initial investigative steps. Successful technologies demonstrated through these studies may be incorporated into the NHGRI's Technology Integration Center activities in subsequent years, further facilitating innovation in genomic research. A Notice of Funding Opportunity (NOFO) will be released in 2025 with an application deadline anticipated in 2026, using the U01 funding mechanism. This advance notice allows potential applicants to form collaborations and prepare responsive projects aligned with the initiative’s goals. The program is managed by the NHGRI under the Department of Health and Human Services, with Lisa H. Chadwick serving as the point of contact for inquiries. The program’s focus is on integrating cutting-edge molecular methodologies to enhance the discovery of genetic underpinnings of rare conditions.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Human Genome Research Institute (NHGRI) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for research on proof of concept studies that explore novel strategies for identifying the gene(s) or variant(s) underlying rare genetic disorders, which take advantage of new and emerging molecular technologies. A primary goal of this initiative is to move beyond the current state of the art approach that uses DNA sequencing-based methods as an initial step. Examples of work that would be within scope include pilot studies using emerging technology like multi-omics, or that evaluate the effectiveness of using molecular methods like RNA-seq or methylation as an initial step. Technologies that show potential in these proof of concept studies will be integrated into the activities of the Technology Integration Center in later years.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in 2025 with an expected application due date in 2026. This NOFO will utilize the U01 activity code.